Comparison of MRD and conventional IMWG response assessment in the GEM-CESAR trial
The GEM-CESAR trial (NCT02415413) investigated a potentially curative strategy for high-risk smoldering multiple myeloma patients, in which the primary endpoint…
Related Articles
The Chronic Lymphocytic Leukemia (CLL) Channel – VJHemOnc
Explore the latest Chronic Lymphocytic Leukemia (CLL) updates, including expert interviews, features, podcasts and e-learning on the VJHemOnc CLL Channel
The evolving use of selinexor in multiple myeloma
Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the use of selinexor in the treatment of multiple myeloma,…
Treatment schedule for ruxolitinib in patients with MPNs and how to assess response
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, outlines the treatment schedule for ruxolitinib in patients with myeloproliferative neoplasms (MPNs) and discusses how to assess if…
Shaping the future of medicine · 24.–25. September 2024 Leipzig
stfom.com Shaping the future of medicine · 24.–25. September 2024 Leipzig
Insights into the management of MDS/MPN overlap syndromes & advice for clinicians
Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, discusses the current approach to managing myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes, which focuses on symptom-directed therapy.…
Optimizing the use of BTK inhibitors in WM: dose reductions & genomic profiling
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the role of BTK inhibitors (BTKis) in the treatment of Waldenström’s macroglobulinemia (WM), highlighting the effectiveness…
Registration – ERIC 2024
Register here REGISTRATION FORM Registration fees On or before 10 June After 10 June After 30 June Regular participant 150 € 250 € 250 €…
An overview of platelet dysfunction in patients with myeloproliferative neoplasms
Chloe James, MD, PhD, University Hospital of Bordeaux, Bordeaux, France, summarizes recent advancements in the understanding of platelet dysfunction in myeloproliferative neoplasms (MPNs). Thrombotic events…
Trial in Focus: NUTRIVENTION – dietary evidence in cancer care
VJHemOnc is excited to share a feature on the rationale, design, and aims of the NUTRIVENTION trial (NCT04920084).
MPN Workshop of the Carolinas 2024 | VJHemOnc
The MPN Workshop of the Carolinas is being held in Asheville, NC, from August 23 -25, 2024. This workshop brings together world-leading experts as they…